Tumor-agnostic ‘Rozlytrek’ seeks PE exemption
By Eo, Yun-Ho | translator Alice Kang
21.04.06 15:38:50
가나다라
0
Expectations that the PE exemption criteria including the single-arm study condition will be met … NTRK inhibitors receive attention
ADC drug ‘Polivy’ also under review as Roche reinforces its rare disease pipeline
Discussions will begin for the listing of Roche's anticancer drug ‘Rozlytrek,’ which may be prescribed regardless of cancer type if specific conditions are met.
According to industry sources, 2 types of anticancer drugs by Roche Korea – Rozlytrek (entrectinib) and Polivy (polatuzumba) – will be up for deliberation by the Review Committee for Cancer Disease of the Health Insurance Reimbursement and Assessment Service (HIRA) tomorrow on the 7th.
Among the two drugs, Rozyltrek, which targets the neurotrophic tyrosine receptor kinase (NTRK), is expected to take the pharmacoeconomic evaluation (PE) exemption track.
Rozlytrek’s approval was based on a sin
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)